Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents

Bacterial enoyl-acyl carrier protein (ACP) reductase (FabI) catalyzes the final step in each elongation cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. High-throughput screening of the Staphylococcus aureus FabI enzyme identifie...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Payne, David J., Miller, William H., Berry, Valerie, Brosky, John, Burgess, Walter J., Chen, Emile, DeWolf, Jr., Walter E., Fosberry, Andrew P., Greenwood, Rebecca, Head, Martha S., Heerding, Dirk A., Janson, Cheryl A., Jaworski, Deborah D., Keller, Paul M., Manley, Peter J., Moore, Terrance D., Newlander, Kenneth A., Pearson, Stewart, Polizzi, Brian J., Qiu, Xiayang, Rittenhouse, Stephen F., Slater-Radosti, Courtney, Salyers, Kevin L., Seefeld, Mark A., Smyth, Martin G., Takata, Dennis T., Uzinskas, Irene N., Vaidya, Kalindi, Wallis, Nicola G., Winram, Scott B., Yuan, Catherine C. K., Huffman, William F.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2002
Sujets:
Mechanisms of Action: Physiological Effects
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC128775/
https://ncbi.nlm.nih.gov/pubmed/12234833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.46.10.3118-3124.2002
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires